Dexamethasone-induced Hiccup in Chemotherapy Patients Treated by Methylprednisolone Rotation

Antiemetic Corticosteroid Rotation From Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated With Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01974024

Enrollment

Registered

2013-11-01

Start date

2013-10-01

Completion date

2016-07-31

Last updated

2017-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dexamethasone-induced Hiccup in Chemotherapy

Keywords

Dexamethasone, Hiccup, Chemotherapy, Methylprednisolone

Brief summary

The aims of this study were to investigate the feasibility of methylprednisolone rotation as treatment of DIH.

Detailed description

we planned a randomized prospective trial for cancer patients with DIH. The objective of the present study was to determine whether the rotation of corticosteroids affects the incidence and intensity of DIH without compromising the antiemetic efficacy.

Interventions

DRUGmethylprednisolone

Adult patients who experienced DIH within 3 days after the administration of dexamethasone as an antiemetic were screened. Eligible patients were randomly assigned to receive dexamethasone or methylprednisolone as an antiemetic (randomization phase). In the next cycle of chemotherapy, the dexamethasone group received methylprednisolone and vice versa in the methylprednisolone group (crossover phase).

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* all solid cancer patients on chemotherapy * age \>18 years * received dexamethasone as an antiemetic

Exclusion criteria

* brain metastases * hiccups before dexamethasone administration * uncontrolled diabetes mellitus * uncontrolled esophagitis or peptic ulcer

Design outcomes

Primary

Measure	Time frame	Description
The intensities of hiccups	2 months	Clinically assessed every cycles(2-4weeks). The intensities of hiccups were assessed using a NRS.

Secondary

Measure	Time frame	Description
The intensities of emesis	2 months	CLinically assessed every cycles (2-4weeks) The intensities of emesis were assessed using a NRS.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026